Eric Dobmeier
Net worth: 90 910 $ as of 31/05/2026
Net worth: 90 910 $ as of 31/05/2026
Mr. Eric L.
Dobmeier is a Chairman at Jade Biosciences, Inc., an Independent Director at Janux Therapeutics, Inc., a Venture Partner at Samsara BioCapital LLC and an Independent Director at Structure Therapeutics, Inc. He is on the Board of Directors at Jade Biosciences, Inc. (United States), Janux Therapeutics, Inc. and Structure Therapeutics, Inc. Mr. Dobmeier was previously employed as a Chairman, President & Chief Executive Officer by Chinook Therapeutics, Inc., a President, Chief Executive Officer & Director by Chinook Therapeutics U.S., Inc., a President, Chief Executive Officer & Director by Chinook Therapeutics, Inc. /Old/, a President & Chief Executive Officer by Silverback Therapeutics, Inc., an Independent Director by Adaptive Biotechnologies Corp., an Independent Director by Atara Biotherapeutics, Inc., an Independent Director by Stemline Therapeutics, Inc., a Chief Operating Officer by Seattle Genetics, Inc., an Attorney by Heller Ehrman LLP, and an Attorney by Venture Law Group.
He also served on the board at Versartis, Inc. He received his undergraduate degree from Princeton University and a graduate degree from Berkeley Law University of California.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 11/06/2026 | 6,231 ( 0.01% ) | 90 910 $ | 31/05/2026 | |
| 17/06/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| STRUCTURE THERAPEUTICS INC. | Director/Board Member | 01/12/2022 |
| JANUX THERAPEUTICS, INC. | Director/Board Member | 19/07/2024 |
| JADE BIOSCIENCES, INC. | Chairman | 28/04/2025 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara BioCapital invests in companies located in the United States. The firm targets companies operating in the fields of biotechnology and pharmaceuticals. It provides early and later stage capital requirements. | Private Equity Investor | 01/05/2024 |
| Companies | Position | End |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Director/Board Member | 10/06/2024 |
| CHINOOK THERAPEUTICS, INC. | Chief Executive Officer | 11/08/2023 |
Chinook Therapeutics U.S., Inc.
Chinook Therapeutics U.S., Inc. Information Technology ServicesTechnology Services Provides information technology services | Chief Executive Officer | 01/08/2023 |
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Director/Board Member | 17/03/2021 |
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders | Director/Board Member | 12/10/2018 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 17 |
|---|---|
Seagen, Inc.
Seagen, Inc. Pharmaceuticals: MajorHealth Technology Develops monoclonal antibody-based therapeutic products for treatment of cancer and immunologic diseases | Health Technology |
Heller Ehrman LLP
Heller Ehrman LLP Miscellaneous Commercial ServicesCommercial Services Provides legal Services | Commercial Services |
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel oncology therapeutics | Health Technology |
Venture Law Group
Venture Law Group Miscellaneous Commercial ServicesCommercial Services Provided law and legal services | Commercial Services |
Princeton University
Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders | Health Technology |
Berkeley Law University of California
Berkeley Law University of California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases | Health Technology |
Adaptive Biotechnologies Corp.
Adaptive Biotechnologies Corp. BiotechnologyHealth Technology Develops minimal residual disease and immune medicine | Health Technology |
Silverback Therapeutics, Inc.
Silverback Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara BioCapital invests in companies located in the United States. The firm targets companies operating in the fields of biotechnology and pharmaceuticals. It provides early and later stage capital requirements. | Finance |
Chinook Therapeutics, Inc. /Old/
Chinook Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops precision medicines for kidney diseases | Commercial Services |
Chinook Therapeutics U.S., Inc.
Chinook Therapeutics U.S., Inc. Information Technology ServicesTechnology Services Provides information technology services | Technology Services |
Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc. BiotechnologyHealth Technology Provides gene therapy services | Health Technology |
Structure Therapeutics, Inc.
Structure Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops molecule therapeutics to treat chronic diseases | Health Technology |
Janux Therapeutics, Inc.
Janux Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage company that develops precision engineered immunotherapies | Health Technology |
Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes medicines for kidney diseases | Health Technology |
Select your edition
All financial news and data tailored to specific country editions